HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PBH
Prestige Consumer Healthcare Inc.
PBH's fundamentals are mixed: it turned 18% of its revenue into free cash flow, but its operating margin fell 5 points to 25%. At 14x earnings, it's trading in line with its usual 15x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PBH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Weak |
PBH's revenue, profitability and cash flow are currently healthy, but its balance sheet is weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PBH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.5x | $45.32 | — |
| Cheap | 13x | $41.99 | -7.4% |
| Current | 14x | $45.32 | — |
| Fair | 15x | $48.52 | +7.1% |
| Expensive | 18x | $57.31 | +26% |
Historical ranges are pointers, not guarantees.
PBH's PE is in its cheap range at 14x. If earnings grow as analysts expect, today's price would be 9.5x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PBH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for PBH, but weaker profitability.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PBH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.78 | +48% |
| Q3 2026 | $3.24 | -20% |
| Q2 2026 | $3.57 | -16% |
| Q1 2026 | $3.91 | -8.9% |
| Q4 2025 | $3.78 | -11% |
| Q3 2025 | $4.03 | -1.9% |
| Q2 2025 | $4.26 | +4.2% |
| Q1 2025 | $4.29 | +2.9% |
| Q4 2024 | $4.27 | +$5.88 |
PBH has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over PBH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PBH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $336.3M | +23% |
| Q2 2026 | $265.7M | +6.5% |
| Q1 2026 | $281.6M | -5% |
| Q4 2025 | $283.4M | -2.4% |
| Q3 2025 | $274.1M | -3.4% |
| Q2 2025 | $249.5M | -6.6% |
| Q1 2025 | $296.5M | +7% |
| Q4 2024 | $290.3M | +2.7% |
PBH's revenue has picked up after four years of holding roughly level: $336M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | -5.1 points |
| Q2 2026 | 20% | -9 points |
| Q1 2026 | 27% | -3 points |
| Q4 2025 | 29% | -2.6 points |
| Q3 2025 | 29% | -0.7 points |
| Q2 2025 | 29% | +1.8 points |
| Q1 2025 | 30% | +0.2 points |
| Q4 2024 | 32% | +1 points |
PBH has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PBH on cash flow, with more consistent year-over-year improvement.
PBH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $34.2M | -38% |
| Q2 2026 | $67.1M | -14% |
| Q1 2026 | $37.6M | -36% |
| Q4 2025 | $75.3M | +18% |
| Q3 2025 | $55.4M | -18% |
| Q2 2025 | $78.2M | +46% |
| Q1 2025 | $58.4M | -8.5% |
| Q4 2024 | $63.5M | -8.6% |
PBH's free cash flow has been positive every quarter for seven years: $214M over the past year, down 16% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PBH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PBH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -11K shares |
| 1 year | -3.4% | -1.7M shares |
| 3 years | -5% | -2.5M shares |
| 5 years | -6.3% | -3.2M shares |
| Available history | -6.4% | -3.2M shares |
PBH has 48M diluted shares, down 3.4% from a year ago, with $47M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $690,000 |
| Q4 2025 | $45.8M |
| Q3 2025 | $75M |
| Q2 2025 | $34.8M |
| Q1 2025 | $11.3M |
| Q4 2024 | $2.4M |
PBH spent $47M buying back its own shares over the past year, down 62% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PBH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.2x | High |
| Q2 2026 | 6.0x | High |
| Q1 2026 | 2.7x | Moderate |
| Q4 2025 | 2.8x | Moderate |
| Q3 2025 | 2.4x | Moderate |
| Q2 2025 | 2.3x | Moderate |
| Q1 2025 | 2.4x | Moderate |
| Q4 2024 | 2.6x | Moderate |
PBH's net debt is about 6.2 years of its operating earnings (EBITDA), up from 2.4 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PBH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.8 | Neutral |
| Stochastic | 25.2 | Neutral |
PBH's weekly RSI is 42 (neutral) and its Stochastic is 25 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PBH PE vs Healthcare Sector
| Metric | PBH | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 46% below |
| PE % | 29 | 29 | Same percentile |
PBH is trading at 14x earnings, a 46% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PBH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $46.9 | 3.4% below |
| 20 week MA | $48.9 | 7.3% below |
| 50 week MA | $54.7 | 17% below |
| 100 week MA | $65.0 | 30% below |
| 200 week MA | $65.3 | 31% below |
PBH is in a downtrend: it's below all five of its weekly moving averages, and 31% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PBH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.7 | $34.9 | -14% |
| 2021 | $34.9 | $61.9 | +77% |
| 2022 | $61.9 | $62.0 | +0.2% |
| 2023 | $62.0 | $61.2 | -1.3% |
| 2024 | $61.2 | $78.5 | +28% |
| 2025 | $78.5 | $62.8 | -20% |
| 2026 YTD | $62.8 | $45.3 | -28% |
PBH has the edge over HIMS on returns for 2026, with the stronger performance.